MiraXion® is a new medicinal product for the treatment of Huntington's disease. The product is designated as an Orphan Medicinal Product by both the FDA and the EMEA. MiraXion is currently in Phase III clinical trials conducted by Amarin Neuroscience Ltd.. Scil Technology retains the marketing rights to MiraXion in certain European countries such as Germany, France, BeNeLux, Austria, Switzerland, Poland, Czech Republic, Slovakia and Turkey.

MiraXion® is a semi-synthetic, highly purified derivative of the n-3 fatty acid eicosapentaenoate (EPA). The mechanism of action is believed to involve the stabilisation of mitochondrial integrity in compromised neurons, thereby preventing or slowing progression from neuronal dysfunction to cell death.

Huntington´s disease, previously known as Huntington's chorea, is a rare, hereditary neurodegenerative brain disease. It is characterised by a combination of movement abnormalities and personality changes progressing to mental dementia. Onset of the disease is usually in the fourth decade of life but may also occasionally occur in early childhood or late life. The symptoms consist of choreatic movement disorders in addition to a progressive loss of control of the fine motor movements. In the early stages of the disease, activities such as tying shoe laces or holding a glass without spilling the contents become difficult. As the disease progress, there are organic personality changes and, in the final stage of the disease, there is a profound dementia.

Further information on MiraXion® can be found here: http://www.amarincorp.com/news.cfm